Stock 603139 SHAANXI KANGHUI PHARMACEUTICAL CO., LTD.
Add to a list
To use this feature you must be a member
Log inSign up

News Shaanxi Kanghui Pharmaceutical Co., Ltd.

Equities

603139

CNE100002XT3

End-of-day quote Shanghai S.E.
Other stock markets
 06:00:00 2024-04-29 pm EDT 		5-day change 1st Jan Change
13.94 CNY +0.65% Intraday chart for Shaanxi Kanghui Pharmaceutical Co., Ltd. +10.90% -25.73%
Apr. 26 Shaanxi Kanghui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024 CI
Mar. 15 Kanghui Pharmaceutical to Earn 151 Million Yuan from Kelavi Buyback MT

Summary

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Shaanxi Kanghui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2024
CI
Kanghui Pharmaceutical to Earn 151 Million Yuan from Kelavi Buyback
MT
Kanghui Pharma Sanctioned Over Failure to Disclose M&A Deal
MT
Shaanxi Kanghui Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023
CI
Kanghui Pharma Denies Speculations of Unit’s Involvement in Production of Weight-Loss Drugs
MT
Shaanxi Kanghui Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023
CI
Shaanxi Kanghui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023
CI
Sichuan Chunsheng Pharmaceutical Group Co., Ltd. announced that it expects to receive CNY 56.795265 million in funding from Shaanxi Kanghui Pharmaceutical Co., Ltd.
CI
Shaanxi Kanghui Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022
CI
Shaanxi Kanghui Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022
CI
Shaanxi Kanghui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
Shaanxi Kanghui Pharmaceutical Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021
CI
Shaanxi Kanghui Pharmaceutical Co., Ltd. completed the acquisition of an additional 10.7143% minority stake in Hubei Kelawei Biopharmaceutical Co., Ltd. from Xi'an Taifeng Pharmaceutical Investment Partnership (Limited Partnership).
CI
Hubei Kelawei Biopharmaceutical Co., Ltd. announced that it has received CNY 39.58 million in funding from Shaanxi Kanghui Pharmaceutical Co., Ltd.
CI
Shaanxi Kanghui Pharmaceutical Co., Ltd. agreed to acquire an additional 10.7143% minority stake in Hubei Kelawei Biopharmaceutical Co., Ltd. from Xi'an Taifeng Pharmaceutical Investment Partnership (Limited Partnership) for CNY 30 million.
CI
Hubei Kelawei Biopharmaceutical Co., Ltd. announced that it expects to receive CNY 39.58 million in funding from Shaanxi Kanghui Pharmaceutical Co., Ltd.
CI
Shaanxi Kanghui Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2021
CI
Shaanxi Kanghui Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2021
CI
Shaanxi Kanghui Pharmaceutical Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021
CI
Shaanxi Kanghui Pharmaceutical Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2020
CI
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. 603139 Stock
  4. News Shaanxi Kanghui Pharmaceutical Co., Ltd.